Delving into the Latest Updates on Shandong Diai Biotechnology Co. Ltd. with Synapse

Overview

Tags

Immune System Diseases

Hemic and Lymphatic Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

JAK(Janus kinase)	1
HIV integrase	1

[Translation] Safety, tolerability, pharmacokinetics and antiviral pharmacodynamics of ACC017 tablets alone or in combination with nucleoside backbone drugs for short-term administration in adults with naive human immunodeficiency virus type 1 (HIV-1): a randomized, double-blind, placebo/dose parallel-controlled, dose-escalation/proof-of-concept phase Ib/IIa clinical trial

评价HIV感染者连续口服ACC017片的安全性和耐受性；评价HIV感染者连续口服ACC017片的药代动力学特征；评价抗HIV的初步疗效；评估药物的量效关系。

[Translation]

To evaluate the safety and tolerability of continuous oral administration of ACC017 tablets in HIV-infected patients; to evaluate the pharmacokinetic characteristics of continuous oral administration of ACC017 tablets in HIV-infected patients; to evaluate the preliminary anti-HIV efficacy; and to assess the dose-effect relationship of the drug.

Start Date28 Aug 2024

Sponsor / Collaborator

Jiangsu Aidea Pharmaceutical Co., Ltd.

[+3]

100 Clinical Results associated with Shandong Diai Biotechnology Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shandong Diai Biotechnology Co. Ltd.

Login to view more data

100 Deals associated with Shandong Diai Biotechnology Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shandong Diai Biotechnology Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

NDA/BLA

Login to view more data